Prognostic Impact of Hypermethylated SFRP1, SFRP2 and Over Expression of CD25 in Acutemyeloid LeukemiaDalia A Nigm*, Azza A Abo Elfadle and Mohamed Z Abd Elrahman
Department of Clinical Pathology, Faculty of Medicine, Assiut University, Egypt
- *Corresponding Author:
- Dalia A Nigm, M.D.
Department of Clinical Pathology
Faculty of Medicine
Assiut University, Egypt
E-mail: [email protected]
Received date: October 20, 2016; Accepted date: November 03, 2016; Published date: November 10, 2016
Citation: Nigm DA, Elfadle AAA, Abd Elrahman MZ (2016) Prognostic Impact of Hypermethylated SFRP1, SFRP2 and Over Expression of CD25 in Acutemyeloid Leukemia. Clon Transgen 5:156. doi: 10.4172/2168-9849.1000156
Copyright: © 2016 Nigm DA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Objective: To study the epigenetic dysfunction of SFRP1, SFRP2 and expression of interleukin-2 receptor α chain (IL2Rα, also known as CD25) in acute myeloblastic leukaemia (AML).
Methods: We study the methylation profile of SFRP1, SFRP2 in AML cells by methylation-speciÃ¯Â¬Âc polymerase chain reaction (MSP) and the hyperexpression of IL2Rα (CD25) by flow-cytometry.
Results: We analysed the methylation profile of SFRP1, SFRP 2 in 40 de novo AML patients. The percentage of hypermethylation in the patient samples were 37.5% for SFRP1 and 12.5% for SFRP2. CD25 was positive in 12 (30%) of 40 patients AML. In patients whom 60 years and younger with intermediate risk cytogenetics in de novo AML, hypermethylation of SFRP1 and CD25 were accompanied with relapse (P=0.024).
Conclusion: Our data indicates that in a subgroup of AML patients, hypermethylation of SFRP1 and high expression of CD25 predict relapse.